

**Kentucky Department of Insurance
Financial Impact Statement**

- I. Mandating health insurance coverage of BR 112 HB 68, is not expected to materially increase premiums, based upon our analysis of the proposed mandate and our experience with similar health insurance benefits. The mandate requires health benefit plans provide coverage for injectable epinephrine devices for persons eighteen (18) years of age and under where coverage shall not be subject to any cost-sharing requirements such as co-payments, coinsurance, or deductibles. Our analysis includes health benefit plans, for all fully insured policies in Kentucky, excluding Medicaid and state employees.

The proposed BR 112 HB 68, as described above, is not expected to materially increase the total cost of health care in the Commonwealth, based upon our analysis of the proposed mandate and our experience with similar health insurance benefits. Our analysis includes health benefit plans, for all fully insured policies in Kentucky, excluding Medicaid and state employees.

The proposed BR 112 HB 68, as described above, is not expected to materially increase administrative expenses of insurers, based upon our analysis of the proposed mandate and our experience with similar health insurance benefits. Our analysis includes health benefit plans, for all fully insured policies in Kentucky, excluding Medicaid and state employees.

Our analysis included the use of data and statistics from Kaiser Family Foundation, KY Affordable Care Act (ACA) filings for plan year 2022, The US Census Bureau, The National Library of Medicine, actuarial judgement, and a 2020 Annual Data Report provided by DOI.

Note: It is acknowledged that there is potential for long-term savings if ER and/or urgent care visits are replaced with readily available injectable epinephrine devise administration. This was considered in estimating the fiscal impact, however, a full cost savings analysis was not included due to time and financial constraints.

Disclosure: L&E made several assumptions in performing the analysis. Several of these assumptions are subject to material uncertainty and it is not unexpected that actual results could materially differ from these estimates if a more in-depth analysis were to be performed.

Disclosure: Due to the material disclosure requirements required therein, we must acknowledge that the content of this report may not comply with Actuarial Standard of Practice No. 41 Actuarial Communications.



Brian Stentz, A.S.A. M.A.A.A.
LEWIS & ELLIS, INC.
October 5, 2022



Traci Hughes, F.S.A. M.A.A.A.
LEWIS & ELLIS, INC.
October 5, 2022

Steven P. Clark 10/6/22

(Signature of Commissioner/Date)

FIS Actuarial Form 6-03